Kineta

Aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.

Launch date

2008

Employees

Market cap

Net debt

-

Enterprise valuation

$2m (Public information from May 2024)

Seattle Washington (HQ)

http://kinetabio.com

https://twitter.com/kinetabio https://www.facebook.com/kinetabio https://www.linkedin.com/company/kineta-inc-

Deals in current and previous year:

Yumanity Therapeutics